Abstract:The gastrin-releasing peptide receptor (GRPR), a G protein-coupled receptor, is overexpressed in solid malignancies and particularly in prostate cancer. We synthesized a novel bombesin derivative, [68Ga]Ga-ProBOMB1, evaluated its pharmacokinetics and potential to image GRPR expression with positron emission tomography (PET), and compared it with [68Ga]Ga-NeoBOMB1. ProBOMB1 (DOTA-pABzA-DIG-d-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-ψ(CH2N)-Pro-NH2) was synthesized by solid-phase peptide synthesis. The polyaminocarboxylate chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was coupled to the N-terminal and separated from the GRPR-targeting sequence by a p-aminomethylaniline-diglycolic acid (pABzA-DIG) linker. The binding affinity to GRPR was determined using a cell-based competition assay, whereas the agonist/antagonist property was determined with a calcium efflux assay. ProBOMB1 was radiolabeled with 68GaCl3. PET imaging and biodistribution studies were performed in male immunocompromised mice bearing PC-3 prostate cancer xenografts. Blocking experiments were performed with coinjection of [d-Phe6,Leu-NHEt13,des-Met14]bombesin(6-14). Dosimetry calculations were performed with OLINDA software. ProBOMB1 and the nonradioactive Ga-ProBOMB were obtained in 1.1 and 67% yield, respectively. The K i value of Ga-ProBOMB1 for GRPR was 3.97 ± 0.76 nM. Ga-ProBOMB1 behaved as an antagonist for GRPR. [68Ga]Ga-ProBOMB1 was obtained in 48.2 ± 10.9% decay-corrected radiochemical yield with 121 ± 46.9 GBq/μmol molar activity and >95% radiochemical purity. Imaging/biodistribution studies showed that the excretion of [68Ga]Ga-ProBOMB1 was primarily through the renal pathway. At 1 h postinjection (p.i.), PC-3 tumor xenografts were clearly delineated in PET images with excellent contrast. The tumor uptake for [68Ga]Ga-ProBOMB1 was 8.17 ± 2.57 percent injected dose per gram (% ID/g) and 9.83 ± 1.48% ID/g for [68Ga]Ga-NeoBOMB1, based on biodistribution studies at 1 h p.i. This corresponded to tumor-to-blood and tumor-to-muscle uptake ratios of 20.6 ± 6.79 and 106 ± 57.7 for [68Ga]Ga-ProBOMB1 and 8.38 ± 0.78 and 39.0 ± 12.6 for [68Ga]Ga-NeoBOMB1, respectively. Blockade with [d-Phe6,Leu-NHEt13,des-Met14]bombesin(6-14) significantly reduced the average uptake of [68Ga]Ga-ProBOMB1 in tumors by 62%. The total absorbed dose was lower for [68Ga]Ga-ProBOMB1 in all organs except for bladder compared with [68Ga]Ga-NeoBOMB1. Our data suggest that [68Ga]Ga-ProBOMB1 is an excellent radiotracer for imaging GRPR expression with PET. [68Ga]Ga-ProBOMB1 achieved a similar uptake as [68Ga]Ga-NeoBOMB1 in tumors, with enhanced contrast and lower whole-body absorbed dose.

Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using 18F-Labeled PEGylated RGD-Bombesin Heterodimer 18F-Fb-peg3-glu-rgd-bbn

18F, 64Cu, and68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer

Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

68Ga-Labeled NOTA-RGD-BBN Peptide for Dual Integrin and GRPR-targeted Tumor Imaging

18F-FP-PEG2-β-Glu-RGD2: A Symmetric Integrin αvβ3-Targeting Radiotracer for Tumor PET Imaging

Noninvasive Imaging of Tumor Integrin Expression Using 18 F-labeled RGD Dimer Peptide with PEG 4 Linkers

MicroPET Imaging of Breast Cancer with a Dual-Targeted Molecular Probe 68Ga-Rgd-bbn

68 Ga-labeled Cyclic RGD Dimers with Gly 3 and PEG 4 Linkers: Promising Agents for Tumor Integrin Α V Β 3 PET Imaging

Novel 64 Cu Labeled RGD 2 -BBN Heterotrimers for PET Imaging of Prostate Cancer.

Ga-68-Labeled Cyclic Rgd Dimers With Gly(3) And Peg(4) Linkers: Promising Agents For Tumor Integrin Alpha(V)Beta(3) Pet Imaging

<sup>68</sup>Ga-labeled cyclic RGD dimers with Gly<sub>3</sub> and PEG<sub>4</sub> linkers: promising agents for tumor integrin α<sub>v</sub>β<sub>3</sub> PET imaging

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

Imaging Integrin Alpha(V)Beta(3) And Nrp-1 Positive Gliomas With A Novel Fluorine-18 Labeled Rgd-Atwlppr Heterodimeric Peptide Probe

Imaging Integrin α v β 3 and NRP-1 Positive Gliomas with a Novel Fluorine-18 Labeled RGD-ATWLPPR Heterodimeric Peptide Probe

Peptidic Heterodimer-Based Radiotracer Targeting Fibroblast Activation Protein and Integrin Αvβ3.

Dual Targeting of Integrin αvβ3 and VEGF Receptor Improves PET Imaging of Breast Cancer

Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03

Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue

<SUP>68</SUP>Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer

18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of Αvβ3 Integrin Expression